The contract development and manufacturing organization (CDMO), Olon S.p.A., has unveiled plans to invest in its global high containment manufacturing operations. The international active pharmaceutical ingredient (API) supplier will be rolling out an investment of €27 million over 2022/2023 totally allocated to the expansion of internal expertise and high containment production capacity.

Olon said that it has just completed a new large scale high containment production line (OEL < 1 mg/m3) of about €10 million euros, on its site located in Rodano, Italy where the headquarters is located.

The new line, just inaugurated and already operational, enables Olon to produce highly potent APIs in large-scale product batches ranging from 30 to 250 kg, capable of serving customers along all stages of scale up.

“Now we are one of the few CDMO companies to offer the range of specific integrated capabilities necessary to support the customer from the first clinical phase up to industrialization, regardless of the quantity of product needed and batch size required and regardless of the ongoing molecule development phase,” said Paolo Tubertini, CEO, Olon Group.